
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(1)							
TDANGMITTA	<u></u>	Application Number		10/747,796			
TRANSMITTAL FORM		Filing Date	Filing Date		December 29, 2003		
		First Named Inventor		Thomas E. Barta			
		Art Unit		1625			
(to be used for all correspondence after	r initial filing)	Examiner Name		TBA			
otal Number of Pages in This Submis		Attorney Docket Nu	ımber	3124/5A/U	S 31134A/USA		
				(0734-0000	JI/IOVI)		
		SURES (check all that	t apply)				
Fee Transmittal Form	Drawing(s)	L		rance Communication to TC		
Fee Attached	Licensing-	related Papers	1		mmunication to Board		
Amendment / Reply	Petition		[of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
After Final	Provisiona	Convert to a all Application	[_	Information		
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address			er		
Extension of Time Request	Terminal Disclaimer			Other End			
	Request fo			orm HDP-144	19		
Express Abandonment Request CD, N		OD About to at OD(a)		Reference Return Receip	t Postcard		
Supplemental Information Disclosure Statement	Landscape Table on CD			totalli i tooolp	.,		
Certified Copy of Priority Document(s)	Remarks						
Reply to Missing Parts/ Incomplete Application							
Reply to Missing Parts under 37 CFR1.52 or 1.53							
SIG	NATURE OF	APPLICANT, ATTOR	RNEY, OF	RAGENT			
Firm	Harness, Diekey	& Pierce, P.L.C.					
Signature	//	W NT					
Printed Name							
Date)5	Reg. No.	41,809				
	CERTIFICA	TE OF TRANSMISS	ION/MAI	LING			
hereby certify that this corresponde Service with sufficient postage as f Alexandria, VA 22313-1450 on the da	irst class mail i	in an envelope addres					
Typed or printed name David M		11_		Express Mail Label No.	EV 327050975 US		
Signature	/n/	111		Date	January 31, 2005		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Thomas E. Barta, et al.

Serial No:

10/747,796

Filed:

December 29, 2003

For:

Aromatic Sulfone Hydroxamic Acid Metalloprotease Inhibitors

Confirmation No: Group Art Unit:

6418

1625 TBA

Examiner: Attorney Ref:

3124/5A/US

Pfizer Ref:

31134A/USA

HDP Ref:

6794-000017/DVF

January 31, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Madam/Sir:

71 67 1 17 6 V

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that the cited document be given thorough consideration, and that the Examiner cite it in the prosecution history of the present application by initialing the Form PTO-1449 next to the citation. Applicants request such initialing even if the Examiner does not consider: (1) the document to be sufficiently pertinent to use in a rejection; (2) the document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with. Applicants make this request so that the document becomes cited on the face of a patent issuing on the present application.

Applicants submit this supplemental information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing the document are not admitting that it is necessarily relevant or prior art. Applicants intend no representation that the listed document represents the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance the document listed on the attached form even if not initialed.

Supplemental Information Disclosure Statement Appl. No. 10/747,796 January 31, 2005

The reference cited in this information disclosure statement is a published U.S. patent application. A copy of it therefore is not being provided in accordance with 37 C.F.R. §1.98(d) and MPEP §609 Part III(A)(2). The pending claim set from this application, however, is being enclosed because the claims have been amended and therefore differ from the claims in the published application. Applicants are happy to provide a copy of the cited application upon request from the Examiner.

Applicants request early and favorable consideration of this patent application.

* * * * * * *

Applicants believe that they do not owe any fee in connection with this information disclosure statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Respectfully submitted,

David M. Gryte, PTO Reg. No. 41,809

Harness, Dickey & Pierce 7700 Bonhomme, Suite 400 St. Louis, Missouri 63105

(314) 726-7500 (tel)

(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on January 31, 2005 with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

DMG/PML enclosures

011	EVE	
MAL	3 1 2005	1
BETT.		ر F(

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.	SERIAL NO.		
3124/5A/US (Pfizer Ref. 31134A/USA)	10/747,796		
APPLICANT			
Thomas E. Barta et al.			
FILING DATE	GROUP		
December 29, 2003	1625		

U.S. PATENT D	OCUMENTS	8				
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1. (pending claims enclosed)		U.S. Patent Appl. Publ. No. 2004-0167182 (Appl. No. 10/603,441), including pending claims		Becker et al.	514/357	6/25/03

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translat Yes	ion No

OTHER	DOCUMENTS (including	ling Author, Title, Date, Pertinent Pages, etc.)	
Ref. Desig.	Examiner's Initials		

Examiner:	Date Considered:		